Showing 2651-2660 of 5689 results for "".
- Quest, LabCorp Launch Nationwide COVID-19 Antibody Testing in Pharmacies and Onlinehttps://modernod.com/news/quest-labcorp-launch-nationwide-covid-19-antibody-testing-in-pharmacies-and-online/2477677/Weeks after launching their own COVID-19 molecular testing initiatives, lab giants Quest Diagnostics and LabCorp have begun offering antibody tests nationwide for the next phase of the coronavirus pandemic, according to a FierceBiotech
- Mojo Vision Raises Additional $51 Million to Develop Smart Contact Lenshttps://modernod.com/news/mojo-vision-raises-additional-51-million-to-develop-smart-contact-lens/2477678/Mojo Vision announced it has raised more than $51 million in a Series B-1 investment round to propel the development of its smart contact lens, Mojo Lens. This new round brings Mojo Vision’s total funding to date to more than $159 million. In January, Mojo announced that it is in th
- AAO, ASCRS, and OOSS Develop Checklist for Reopening Ophthalmic Surgery Centershttps://modernod.com/news/ooss-aao-and-ascrs-develop-checklist-for-reopening-ophthalmic-surgery-centers/2477669/To support the safe reopening of care, the American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), and the Outpatient Ophthalmic Surgery Society (OOSS), developed a checklist<
- Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of Dextenza for Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-topline-results-of-phase-3-clinical-trial-of-dextenza-for-allergic-conjunctivitis/2477659/Ocular Therapeutix announced topline results from its phase 3 clinical trial to evaluate the safety and efficacy of Dextenza for the treatment of ocular itching associated with allergic conjunctivitis (AC). In the phase 3 trial, Dextenza met all prespecified primary endpoints as demonstrated by a
- Congress Reaches Deal That Includes $75B for Hospitals After Requests From Providershttps://modernod.com/news/congress-reaches-deal-that-includes-75b-for-hospitals-after-requests-from-providers/2477629/Congressional and White House leaders have reached a deal to provide $75 billion for hospitals and another $25 billion for testing, according to a report from CNN, as
- Novartis to Conduct Study of Hydroxychloroquine for Hospitalized Patients With COVID-19 Diseasehttps://modernod.com/news/novartis-to-conduct-study-of-hydroxychloroquine-for-hospitalized-patients-with-covid-19-disease/2477617/Novartis announced Monday that it reached an agreement with the FDA to begin a phase 3 study evaluating the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The trial, which will be conduct
- Novartis Implementing Programs to Assist Optometrists During COVID-19https://modernod.com/news/novartis-implementing-programs-to-assist-optometrists-during-covid-19/2477609/Novartis announced that it is implementing the following to ensure optometrists are well-equipped to provide care for patients during the COVID-19 pandemic: Strengthening the online, self-service sample website –
- Call for Nominations Issued for the 2020 Bonnie Strickland Champion for Children’s Vision Awardhttps://modernod.com/news/call-for-nominations-issued-for-the-2020-bonnie-strickland-champion-for-childrens-vision-award/2477595/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has issued the call for nominations for the sixth annual “Bonnie Strickland Champion for Children’
- TearClear Appoints Robert J. Dempsey Chief Executive Officerhttps://modernod.com/news/tearclear-appoints-robert-j-dempsey-chief-executive-officer/2477596/TearClear announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing, according to a company news release. <
- FDA Quickly Authorizes Its 2nd Blood Filtering Device for COVID-19https://modernod.com/news/fda-quickly-authorizes-its-2nd-blood-filtering-device-for-covid-19/2477585/Shortly after granting an emergency authorization to Terumo BCT’s blood filtering device for COVID-19, the FDA did the same for CytoSorbents’ system, according to a FierceBiotech